Clearside Biomedical, Inc. (CLSD:NASDAQ) closed at $0.410 on October 14, 2026, unchanged on the day. The stock trades 97.6% below its 52-week high of $17.10 and 32.3% above its 52-week low of $0.310. Over the past year, it lost 88.9%. Clearside Biomedical, Inc. is part of the Health Care sector (Major Pharmaceuticals).
| 5D | 6M | 1Y |
|---|---|---|
| 0.00% | +17.14% | -88.93% |
In 252 trading sessions since October 15, 2025, CLSD closed higher on 67 days (27%). Its best day was December 2, 2025 (+91.84%) and its worst was November 24, 2025 (-66.92%). The stock moved 10% or more in a single session 56 times. It opened at least 5% above the previous day's high 107 times.
Clearside BioMedical, Inc., a biopharmaceutical company, develops drug therapies to treat chronic blinding diseases of the eye. Its products include CLS-1001 for the treatment of macular edema associated with non-infectious uveitis; CLS-1003 for the treatment of macular edema associated with retinal vein occlusion; and CLS-1002 program for the treatment of wet age-related macular degeneration. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.
Find more stocks like CLSD with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.